Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alpha-1 antitrypsin - Kamada

Drug Profile

Alpha-1 antitrypsin - Kamada

Alternative Names: A1AT; A1PI; AAT; AAT-IH; AAT-IV; Alpha-1 Antitrypsin; Alpha-1-Antiproteinase; alpha-1-proteinase inhibitor; ALPHA.1-PROTEINASE INHIBITOR HUMAN; Aralast; D1-AAT; G1-AAT; G1-AAT IV; Glassia; Infinia; Inhaled-AAT; IV AAT; Kamada-API; L1-AAT; Prolastin-C

Latest Information Update: 14 Oct 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kamada
  • Developer Kamada; Mount Sinai Hospital (Toronto); Takeda
  • Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Antihyperglycaemics; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Immunomodulators; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Bronchiectasis; Alpha 1-antitrypsin deficiency; Cystic fibrosis; Type 1 diabetes mellitus
  • New Molecular Entity No
  • Available For Licensing Yes - Type 1 diabetes mellitus

Highest Development Phases

  • Marketed Alpha 1-antitrypsin deficiency
  • Phase II/III Graft-versus-host disease; Type 1 diabetes mellitus
  • Phase II Bronchiectasis; Cystic fibrosis; Lung transplant rejection

Most Recent Events

  • 30 Sep 2020 Kamada and myTomorrows complete an early access programme in Graft-versus-host disease (Treatment-experienced) in Europe (IV) (NCT03172455)
  • 18 May 2020 Kamada temporarily suspends enrolment in the phase III InnovAATe trial in Alpha-1 antrypsin deficiency due to COVID-19 pandemic
  • 14 Nov 2019 Kamada submits amended IND application to the US FDA for alpha-1 antitrypsin deficiency
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top